Document is current
Any future updates will be listed below
-
Authors
Zhou, Sufeng
Liu, Wei
Zhou, Chen
Zhang, Lingling
Xie, Lijun
Xu, Zhaoqiang
Wang, Lu
Zhao, Yuqing
Guo, Lian
Chen, Juan
Ding, Lieming
Mao, Li
Tao, Yi
Zhang, Chen
Ding, Sijia
Shao, Feng https://orcid.org/0000-0001-8861-7299
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03804541 at ClinicalTrials.govDocuments that mention this clinical trial
Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration
https://doi.org/10.1007/s00280-020-04159-0
-
Funding
Funding for this research was provided by:
Betta Pharmaceuticals Co., Ltd.
National Major Science and Technology Projects of China (2018ZX09734-007)
- License Information
-
More Information
Article History
Received: 30 April 2020
Accepted: 30 September 2020
First Online: 12 October 2020
Compliance with ethical standards
:
: Li Mao and Lieming Ding are employees of Betta pharmaceuticals which provided funding for the study. Lingling Zhang, Lian Guo and Yi Tao are employees of WuXi AppTec Co. Ltd. which were responsible for the determination of this study. Other authors have no potential conflicts of interest to report.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
